Immunocore Holdings plcIMCR stock score: 51/100
$26.63 · -3.20% · Scored Nov 19, 2026
- Technical
- 26
- Fundamental
- 57
- News
- 53
The reading
Immunocore Holdings (IMCR) scores 51 out of 100, which reads neutral, higher than 51% of Healthcare stocks and 47% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 57, technicals 26.
Among the fundamentals, Price Target at 100 and Revenue Quality (Quarterly) at 100 score highest, while Earnings Growth (5-Year) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 17 and contrarian oscillators 69 — a split worth reading before trusting the technical total.
News sentiment is neutral at 53; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 37 to 53, and it ends the period where it started.
About Immunocore Holdings
Immunocore (IMCR) is a commercial-stage biotechnology company based in the United Kingdom that develops medicines from its ImmTAX platform, which uses engineered T cell receptors to direct the immune system against specific targets. Its marketed drug, KIMMTRAK, is approved in the United States, Europe and other countries for adults with a form of metastatic uveal melanoma, a rare eye cancer, and it was the first approved therapy of its kind. The company sells KIMMTRAK directly in major markets and through distributors elsewhere, and product sales provide most of its revenue. Its lead pipeline candidate, brenetafusp, targets a protein called PRAME that appears in many cancers and is in late-stage testing in advanced cutaneous melanoma, with studies in other tumors as well. Immunocore also works on candidates for infectious and autoimmune diseases.
Immunocore competes with large cancer drug makers such as Merck, Bristol Myers Squibb and Roche, which sell immunotherapies used in melanoma, and with companies developing T cell receptor and bispecific therapies such as Immatics. Its edge rests on a first-in-class approved product that funds research and on a platform that can reach targets inside cells that antibodies cannot. Investors who follow IMCR stock tend to watch KIMMTRAK sales and patient uptake. Results from the late-stage brenetafusp melanoma trial are closely followed. Pipeline progress, operating expenses and the cash balance are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward IMCR’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
57Pulling it up
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
How the latest quarter's revenue compares with the average of the last four, plus a bonus for steady quarterly revenue.
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
Holding it back
5-year earnings growth evaluates long-term profit trajectory and consistency.
Return on Equity (ROE) measures how efficiently a company generates profits from shareholder equity.
Gross margins show profitability after cost of goods sold.
38 weighted scorers; 1 had no data today and are left out rather than counted as zero.
Technical · daily
23Pulling it up
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
Williams %R (28-period) places the close within the last 28 periods' high-low range.
Holding it back
Where the price sits between its 52-week low and high.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Simple Moving Average (10-period) smooths price action over 10 periods.
61 weighted scorers; 4 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 53
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 37 | 1 |
| Daily | 23 | 3 |
| Weekly | 22 | 2 |
| Monthly | 30 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 51 |
| Nov 18, 2026 | 51 |
| Nov 17, 2026 | 51 |
| Nov 16, 2026 | 52 |
| Nov 15, 2026 | 52 |
| Nov 14, 2026 | 52 |
| Nov 13, 2026 | 52 |
| Nov 12, 2026 | 53 |
| Nov 11, 2026 | 45 |
| Nov 10, 2026 | 46 |
| Nov 8, 2026 | 41 |
| Nov 7, 2026 | 41 |
| Nov 6, 2026 | 41 |
| Nov 5, 2026 | 37 |
| Nov 4, 2026 | 38 |
| Nov 3, 2026 | 40 |
| Nov 2, 2026 | 40 |
| Nov 1, 2026 | 41 |
| Oct 30, 2026 | 40 |
| Oct 29, 2026 | 43 |
| Oct 28, 2026 | 45 |
| Oct 27, 2026 | 44 |
| Oct 26, 2026 | 42 |
| Oct 25, 2026 | 41 |
| Oct 24, 2026 | 41 |
| Oct 23, 2026 | 41 |
| Oct 22, 2026 | 45 |
| Oct 21, 2026 | 45 |
| Oct 20, 2026 | 45 |
| Oct 19, 2026 | 40 |
| Oct 18, 2026 | 39 |
| Oct 17, 2026 | 39 |
| Oct 16, 2026 | 39 |
| Oct 15, 2026 | 39 |
| Oct 14, 2026 | 37 |
| Oct 13, 2026 | 37 |
| Oct 12, 2026 | 38 |
| Oct 11, 2026 | 39 |
| Oct 10, 2026 | 39 |
| Oct 9, 2026 | 39 |
| Oct 8, 2026 | 38 |
| Oct 7, 2026 | 38 |
| Oct 6, 2026 | 38 |
| Oct 5, 2026 | 38 |
| Oct 4, 2026 | 38 |
| Oct 3, 2026 | 38 |
| Oct 2, 2026 | 38 |
| Oct 1, 2026 | 39 |
| Sep 30, 2026 | 38 |
| Sep 29, 2026 | 39 |
| Sep 28, 2026 | 39 |
| Sep 27, 2026 | 39 |
| Sep 26, 2026 | 39 |
| Sep 25, 2026 | 39 |
| Sep 24, 2026 | 42 |
| Sep 23, 2026 | 42 |
| Sep 22, 2026 | 42 |
| Sep 21, 2026 | 43 |
| Sep 20, 2026 | 42 |
| Sep 19, 2026 | 42 |
| Sep 18, 2026 | 42 |
| Sep 17, 2026 | 44 |
| Sep 16, 2026 | 40 |
| Sep 15, 2026 | 41 |
| Sep 14, 2026 | 43 |
| Sep 13, 2026 | 43 |
| Sep 12, 2026 | 43 |
| Sep 11, 2026 | 43 |
| Sep 10, 2026 | 45 |
| Sep 9, 2026 | 46 |
| Sep 8, 2026 | 48 |
| Sep 7, 2026 | 50 |
| Sep 6, 2026 | 50 |
| Sep 5, 2026 | 50 |
| Sep 4, 2026 | 49 |
| Sep 3, 2026 | 52 |
| Sep 2, 2026 | 52 |
| Sep 1, 2026 | 52 |
| Aug 31, 2026 | 50 |
| Aug 30, 2026 | 50 |
| Aug 29, 2026 | 50 |
| Aug 28, 2026 | 50 |
| Aug 27, 2026 | 50 |
| Aug 26, 2026 | 51 |
| Aug 25, 2026 | 52 |
| Aug 24, 2026 | 51 |
| Aug 23, 2026 | 51 |
Key facts
- Market cap
- $1.4B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 0.81
- Risk grade (1–10)
- —
- Next earnings
- Nov 6, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| ABSI Absci | $1.4B | 27 |
| ANAB AnaptysBio | $1.4B | 69 |
| RAPP Rapport Therapeutics | $1.4B | 32 |
| NBTX Nanobiotix | $1.4B | 48 |
| TYRA Tyra Biosciences | $1.4B | 31 |
| NUVB Nuvation Bio | $1.3B | 40 |
Questions
What is IMCR's stock rating today?
IMCR scores 51/100 (Neutral) as of Nov 19, 2026: technical 26, fundamental 57, and news sentiment 53, which is shown but not counted. Scores are recomputed every night.
What does Immunocore Holdings do?
Immunocore (IMCR) is a commercial-stage biotechnology company based in the United Kingdom that develops medicines from its ImmTAX platform, which uses engineered T cell receptors to direct the immune system against specific targets. Its marketed drug, KIMMTRAK, is approved in the United States, Europe and other countries for adults with a form of metastatic uveal melanoma, a rare eye cancer, and it was the first approved therapy of its kind.
Is IMCR stock a buy?
The score is not a buy or sell recommendation. A 51 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the IMCR score calculated?
99 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 61 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/imcr/"><img src="https://stocksscores.com/stocks/imcr/badge.svg" alt="IMCR stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/imcr/)